\begin{longtable}{p{0.2\textwidth}p{0.1\textwidth}p{0.1\textwidth}p{0.1\textwidth}p{0.1\textwidth}p{0.1\textwidth}p{0.1\textwidth}p{0.1\textwidth}}
   & 2018 & 2019 & 2020 & 2021 & 2022 & 2023 & Overall \\ 
  \hline 
\endfirsthead 
\multicolumn{8}{p{\textwidth}}{{ \bfseries \tablename \thetable{} -- continued from previous page}} \ 
\hline Feature & 2018 & 2019 & 2020 & 2021 & 2022 & 2023 & Overall \\ \hline 
\endhead 
\hline \multicolumn{8}{p{\textwidth}}{{Continued on next page}} \\ \hline 
\endfoot 
\hline 
\endlastfoot 
 \hline
 & (N=20420) & (N=27467) & (N=30177) & (N=51298) & (N=78631) & (N=66569) & (N=274562) \\ 
  Age &  &  &  &  &  &  &  \\ 
    Mean (SD) & 58 (12) & 58 (13) & 58 (13) & 58 (13) & 56 (14) & 55 (14) & 57 (13) \\ 
  Age Group &  &  &  &  &  &  &  \\ 
    0-17 & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    18-44 & 3192 (16\%) & 4297 (16\%) & 4751 (16\%) & 9175 (18\%) & 17894 (23\%) & 16606 (25\%) & 55915 (20\%) \\ 
    45-64 & 11146 (55\%) & 14622 (53\%) & 15725 (52\%) & 25675 (50\%) & 39564 (50\%) & 33429 (50\%) & 140161 (51\%) \\ 
    65+ & 6082 (30\%) & 8548 (31\%) & 9701 (32\%) & 16448 (32\%) & 21173 (27\%) & 16534 (25\%) & 78486 (29\%) \\ 
  Sex &  &  &  &  &  &  &  \\ 
    Female & 11969 (59\%) & 15747 (57\%) & 17414 (58\%) & 31269 (61\%) & 52395 (67\%) & 46385 (70\%) & 175179 (64\%) \\ 
    Male & 8398 (41\%) & 11653 (42\%) & 12718 (42\%) & 19967 (39\%) & 26180 (33\%) & 20156 (30\%) & 99072 (36\%) \\ 
    Unknown & 53 (0\%) & 67 (0\%) & 45 (0\%) & 62 (0\%) & 56 (0\%) & 28 (0\%) & 311 (0\%) \\ 
  Race &  &  &  &  &  &  &  \\ 
    White & 15130 (74\%) & 19739 (72\%) & 21242 (70\%) & 36010 (70\%) & 55641 (71\%) & 47433 (71\%) & 195195 (71\%) \\ 
    Black & 3370 (17\%) & 4551 (17\%) & 5064 (17\%) & 8150 (16\%) & 13177 (17\%) & 10442 (16\%) & 44754 (16\%) \\ 
    Asian & 368 (2\%) & 680 (2\%) & 835 (3\%) & 1565 (3\%) & 2006 (3\%) & 1607 (2\%) & 7061 (3\%) \\ 
    AI or AN & 136 (1\%) & 185 (1\%) & 217 (1\%) & 421 (1\%) & 601 (1\%) & 416 (1\%) & 1976 (1\%) \\ 
    NH or PI & 64 (0\%) & 99 (0\%) & 123 (0\%) & 231 (0\%) & 374 (0\%) & 273 (0\%) & 1164 (0\%) \\ 
    Other Race & 676 (3\%) & 1257 (5\%) & 1636 (5\%) & 3086 (6\%) & 4331 (6\%) & 3825 (6\%) & 14811 (5\%) \\ 
    Declined to answer & 125 (1\%) & 185 (1\%) & 286 (1\%) & 587 (1\%) & 620 (1\%) & 640 (1\%) & 2443 (1\%) \\ 
    Unknown & 551 (3\%) & 771 (3\%) & 774 (3\%) & 1248 (2\%) & 1881 (2\%) & 1933 (3\%) & 7158 (3\%) \\ 
  Ethnicity &  &  &  &  &  &  &  \\ 
    Hispanic or Latino & 1317 (6\%) & 2279 (8\%) & 3111 (10\%) & 5894 (11\%) & 8600 (11\%) & 7274 (11\%) & 28475 (10\%) \\ 
    Not Hispanic or Latino & 17587 (86\%) & 23186 (84\%) & 25090 (83\%) & 42485 (83\%) & 66170 (84\%) & 55999 (84\%) & 230517 (84\%) \\ 
    Declined to answer & 189 (1\%) & 320 (1\%) & 355 (1\%) & 682 (1\%) & 807 (1\%) & 852 (1\%) & 3205 (1\%) \\ 
    Unknown & 1327 (6\%) & 1682 (6\%) & 1621 (5\%) & 2237 (4\%) & 3054 (4\%) & 2444 (4\%) & 12365 (5\%) \\ 
  T2D & 17169 (84\%) & 22903 (83\%) & 24469 (81\%) & 37286 (73\%) & 47421 (60\%) & 32612 (49\%) & 181860 (66\%) \\ 
  Obesity or Overweight & 15452 (76\%) & 21371 (78\%) & 22937 (76\%) & 41005 (80\%) & 68556 (87\%) & 60394 (91\%) & 229715 (84\%) \\ 
  FDA-labeled Use &  &  &  &  &  &  &  \\ 
    T2D & 12760 (62\%) & 16591 (60\%) & 21980 (73\%) & 37577 (73\%) & 51744 (66\%) & 36583 (55\%) & 177235 (65\%) \\ 
    Obesity & 310 (2\%) & 435 (2\%) & 1306 (4\%) & 3997 (8\%) & 7448 (9\%) & 13000 (20\%) & 26496 (10\%) \\ 
    Unknown & 7350 (36\%) & 10441 (38\%) & 6891 (23\%) & 9724 (19\%) & 19439 (25\%) & 16986 (26\%) & 70831 (26\%) \\ 
  Generic &  &  &  &  &  &  &  \\ 
    Semaglutide & 1624 (8\%) & 6574 (24\%) & 11060 (37\%) & 25659 (50\%) & 47305 (60\%) & 49053 (74\%) & 141275 (51\%) \\ 
    Dulaglutide & 7548 (37\%) & 10291 (37\%) & 10700 (35\%) & 16335 (32\%) & 16504 (21\%) & 6952 (10\%) & 68330 (25\%) \\ 
    Liraglutide & 7943 (39\%) & 8127 (30\%) & 6650 (22\%) & 7923 (15\%) & 7491 (10\%) & 2802 (4\%) & 40936 (15\%) \\ 
    Tirzepatide & 1 (0\%) & 0 (0\%) & 0 (0\%) & 1 (0\%) & 6635 (8\%) & 7483 (11\%) & 14120 (5\%) \\ 
    Exenatide & 2830 (14\%) & 2070 (8\%) & 1376 (5\%) & 972 (2\%) & 344 (0\%) & 113 (0\%) & 7705 (3\%) \\ 
    Lixisenatide & 474 (2\%) & 405 (1\%) & 391 (1\%) & 408 (1\%) & 352 (0\%) & 166 (0\%) & 2196 (1\%) \\ 
  Brand &  &  &  &  &  &  &  \\ 
    Ozempic & 245 (1\%) & 1222 (4\%) & 5328 (18\%) & 11994 (23\%) & 18779 (24\%) & 16546 (25\%) & 54114 (20\%) \\ 
    Rybelsus & 0 (0\%) & 110 (0\%) & 1462 (5\%) & 4668 (9\%) & 6585 (8\%) & 3698 (6\%) & 16523 (6\%) \\ 
    Wegovy & 0 (0\%) & 0 (0\%) & 0 (0\%) & 1824 (4\%) & 4882 (6\%) & 12074 (18\%) & 18780 (7\%) \\ 
    Trulicity & 7548 (37\%) & 10291 (37\%) & 10700 (35\%) & 16335 (32\%) & 16505 (21\%) & 6952 (10\%) & 68331 (25\%) \\ 
    Victoza & 1480 (7\%) & 1671 (6\%) & 2184 (7\%) & 2658 (5\%) & 1612 (2\%) & 695 (1\%) & 10300 (4\%) \\ 
    Saxenda & 310 (2\%) & 435 (2\%) & 1306 (4\%) & 2173 (4\%) & 2566 (3\%) & 926 (1\%) & 7716 (3\%) \\ 
    Mounjaro & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 6635 (8\%) & 7483 (11\%) & 14118 (5\%) \\ 
    Bydureon & 732 (4\%) & 714 (3\%) & 824 (3\%) & 757 (1\%) & 249 (0\%) & 84 (0\%) & 3360 (1\%) \\ 
    Byetta & 107 (1\%) & 81 (0\%) & 53 (0\%) & 65 (0\%) & 31 (0\%) & 11 (0\%) & 348 (0\%) \\ 
    Soliqua & 226 (1\%) & 230 (1\%) & 312 (1\%) & 377 (1\%) & 321 (0\%) & 146 (0\%) & 1612 (1\%) \\ 
    Unknown & 9772 (48\%) & 12713 (46\%) & 8008 (27\%) & 10447 (20\%) & 20466 (26\%) & 17954 (27\%) & 79360 (29\%) \\ 
  Atrial Fibrilation & 1589 (8\%) & 2259 (8\%) & 2487 (8\%) & 4006 (8\%) & 5453 (7\%) & 4200 (6\%) & 19994 (7\%) \\ 
  Asthma & 3472 (17\%) & 4791 (17\%) & 5193 (17\%) & 9133 (18\%) & 15575 (20\%) & 13657 (21\%) & 51821 (19\%) \\ 
  CKD & 3110 (15\%) & 4584 (17\%) & 5371 (18\%) & 8529 (17\%) & 11391 (14\%) & 7853 (12\%) & 40838 (15\%) \\ 
  COPD & 2032 (10\%) & 2595 (9\%) & 2900 (10\%) & 4444 (9\%) & 6038 (8\%) & 4621 (7\%) & 22630 (8\%) \\ 
  Glaucoma & 545 (3\%) & 793 (3\%) & 823 (3\%) & 1295 (3\%) & 1866 (2\%) & 1406 (2\%) & 6728 (2\%) \\ 
  Heart Failure & 1987 (10\%) & 2836 (10\%) & 3299 (11\%) & 4991 (10\%) & 6663 (8\%) & 4819 (7\%) & 24595 (9\%) \\ 
  Hyperlipidemia & 15525 (76\%) & 20678 (75\%) & 21541 (71\%) & 34350 (67\%) & 52382 (67\%) & 42372 (64\%) & 186848 (68\%) \\ 
  Hypertension & 15809 (77\%) & 21070 (77\%) & 21819 (72\%) & 35087 (68\%) & 53077 (68\%) & 42434 (64\%) & 189296 (69\%) \\ 
  Ischemic Heart Disease & 2273 (11\%) & 3141 (11\%) & 3318 (11\%) & 4729 (9\%) & 6300 (8\%) & 4522 (7\%) & 24283 (9\%) \\ 
  Acute MI & 966 (5\%) & 1333 (5\%) & 1426 (5\%) & 1979 (4\%) & 2730 (3\%) & 1860 (3\%) & 10294 (4\%) \\ 
  Ischemic Stroke & 70 (0\%) & 128 (0\%) & 109 (0\%) & 183 (0\%) & 225 (0\%) & 169 (0\%) & 884 (0\%) \\ 
  Major Depressive Disorder & 4051 (20\%) & 5763 (21\%) & 6037 (20\%) & 10644 (21\%) & 17624 (22\%) & 14854 (22\%) & 58973 (21\%) \\ 
  Osteoporosis & 648 (3\%) & 941 (3\%) & 1011 (3\%) & 1770 (3\%) & 2745 (3\%) & 2343 (4\%) & 9458 (3\%) \\ 
  Bariatric Surgery & 399 (2\%) & 560 (2\%) & 634 (2\%) & 1323 (3\%) & 2527 (3\%) & 2401 (4\%) & 7844 (3\%) \\ 
  Metformin & 12820 (63\%) & 17234 (63\%) & 18377 (61\%) & 29048 (57\%) & 37075 (47\%) & 25673 (39\%) & 140227 (51\%) \\ 
  SGLT2i & 4450 (22\%) & 5678 (21\%) & 6225 (21\%) & 10242 (20\%) & 13396 (17\%) & 9002 (14\%) & 48993 (18\%) \\ 
  DPP4 & 4990 (24\%) & 6067 (22\%) & 5943 (20\%) & 7809 (15\%) & 8405 (11\%) & 4748 (7\%) & 37962 (14\%) \\ 
  Sulfonylurea & 6846 (34\%) & 8890 (32\%) & 9351 (31\%) & 13132 (26\%) & 14301 (18\%) & 8381 (13\%) & 60901 (22\%) \\ 
  Insulin & 2609 (13\%) & 3292 (12\%) & 3545 (12\%) & 5350 (10\%) & 6855 (9\%) & 4715 (7\%) & 26366 (10\%) \\ 
  Orlistat & 24 (0\%) & 39 (0\%) & 47 (0\%) & 110 (0\%) & 154 (0\%) & 118 (0\%) & 492 (0\%) \\ 
  Phentermine Topiramate & 205 (1\%) & 201 (1\%) & 153 (1\%) & 294 (1\%) & 465 (1\%) & 396 (1\%) & 1714 (1\%) \\ 
  BMI &  &  &  &  &  &  &  \\ 
    Mean (SD) & 37 (8.2) & 37 (8.4) & 37 (8.5) & 37 (8.7) & 38 (8.7) & 38 (8.3) & 37 (8.5) \\ 
    Missing & 10287 (50.4\%) & 13704 (49.9\%) & 14823 (49.1\%) & 24431 (47.6\%) & 34589 (44.0\%) & 27808 (41.8\%) & 125642 (45.8\%) \\ 
  Weight (in lbs) &  &  &  &  &  &  &  \\ 
    Mean (SD) & 240 (57) & 240 (58) & 240 (60) & 240 (60) & 230 (57) & 230 (55) & 230 (57) \\ 
    Missing & 7267 (35.6\%) & 10361 (37.7\%) & 12850 (42.6\%) & 22469 (43.8\%) & 22351 (28.4\%) & 17555 (26.4\%) & 92853 (33.8\%) \\ 
  HbA1c &  &  &  &  &  &  &  \\ 
    Mean (SD) & 8.4 (1.9) & 8.4 (1.9) & 8.4 (2.0) & 8.0 (2.0) & 7.5 (1.9) & 7.0 (1.8) & 7.8 (2.0) \\ 
    Missing & 4732 (23.2\%) & 6125 (22.3\%) & 6720 (22.3\%) & 12404 (24.2\%) & 24219 (30.8\%) & 24376 (36.6\%) & 78576 (28.6\%) \\ 
  \hline
\caption{Characteristics of patients first prescribed a GLP-1 RA, by year of first prescription.\Abbreviations: 
ADM=anti-diabetic medication,
AI  = American Indian, 
AN = Alaska Native, 
AOM=anti-obesity medication, 
Black = Black or African American, 
BMI = body mass index,
CKD=chronic kidney disease, 
COPD=chronic obstructive pulmonary disease, 
DPP4= dipeptidyl peptidase 4 inhibitor, 
FDA=Food and Drug Administration, 
HbA1c=hemoglobin A1C, 
MI=myocardial infarction, 
NH = Native Hawaiian, 
PI = Pacific Islander, 
SD=standard deviation, 
SGLT2i=sodium/glucose cotransporter-2 inhibitor,
T2D=type 2 diabetes mellitus.} 
\label{tab:table_1_year}
\end{longtable}
